249 related articles for article (PubMed ID: 21386089)
1. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions.
Otake H; Honda Y; Courtney BK; Shimohama T; Ako J; Waseda K; Macours N; Rogers C; Popma JJ; Abizaid A; Ormiston JA; Spaulding C; Cohen SA; Fitzgerald PJ
Circ Cardiovasc Interv; 2011 Apr; 4(2):146-54. PubMed ID: 21386089
[TBL] [Abstract][Full Text] [Related]
2. Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
Abizaid A; Ormiston JA; Fajadet J; Mauri L; Schofer J; Verheye S; Dens J; Thuesen L; Macours N; Qureshi AC; Spaulding C;
EuroIntervention; 2013 Oct; 9(6):721-9. PubMed ID: 23518218
[TBL] [Abstract][Full Text] [Related]
3. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
Ormiston JA; Abizaid A; Spertus J; Fajadet J; Mauri L; Schofer J; Verheye S; Dens J; Thuesen L; Dubois C; Hoffmann R; Wijns W; Fitzgerald PJ; Popma JJ; Macours N; Cebrian A; Stoll HP; Rogers C; Spaulding C;
Circ Cardiovasc Interv; 2010 Dec; 3(6):556-64. PubMed ID: 21062998
[TBL] [Abstract][Full Text] [Related]
4. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
[TBL] [Abstract][Full Text] [Related]
5. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
[TBL] [Abstract][Full Text] [Related]
7. Comparison of zotarolimus-eluting stents with sirolimus-eluting and paclitaxel-eluting stents: intimal hyperplasia and vascular changes assessed by volumetric intravascular ultrasound analysis.
Kang SJ; Mintz GS; Park DW; Lee SW; Kim YH; Lee CW; Han KH; Kim JJ; Park SW; Park SJ
Circ Cardiovasc Interv; 2011 Apr; 4(2):139-45. PubMed ID: 21364151
[TBL] [Abstract][Full Text] [Related]
8. "Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study".
Cervinka P; Costa MA; Angiolillo DJ; Spacek R; Bystron M; Kvasnák M; Veselka J; Nanda H; Futamatsu H; Futamatsu K
Catheter Cardiovasc Interv; 2006 Jun; 67(6):846-51. PubMed ID: 16683273
[TBL] [Abstract][Full Text] [Related]
9. Impact of polymer formulations on neointimal proliferation after zotarolimus-eluting stent with different polymers: insights from the RESOLUTE trial.
Waseda K; Ako J; Yamasaki M; Koizumi T; Sakurai R; Hongo Y; Koo BK; Ormiston J; Worthley SG; Whitbourn RJ; Walters DL; Meredith IT; Fitzgerald PJ; Honda Y
Circ Cardiovasc Interv; 2011 Jun; 4(3):248-55. PubMed ID: 21586691
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study.
Petronio AS; De Carlo M; Branchitta G; Papini B; Ciabatti N; Gistri R; Cortese B; Gherarducci G; Barsotti A
J Am Coll Cardiol; 2007 Feb; 49(5):539-46. PubMed ID: 17276176
[TBL] [Abstract][Full Text] [Related]
11. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
[TBL] [Abstract][Full Text] [Related]
12. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial.
Desch S; Schloma D; Möbius-Winkler S; Erbs S; Gielen S; Linke A; Yu J; Lauer B; Kleinertz K; Dänschel W; Schuler G; Thiele H
JACC Cardiovasc Interv; 2011 Apr; 4(4):452-9. PubMed ID: 21511226
[TBL] [Abstract][Full Text] [Related]
14. Comparison of vascular response to the everolimus-eluting stent versus the paclitaxel-eluting stent: intravascular ultrasound results from the SPIRIT III trial.
Yamasaki M; Tsujino I; Lima-Filho MO; Ako J; Shimohama T; Hasegawa T; Sakurai R; Sudhir K; Stone GW; Waseda K; Honda Y; Fitzgerald PJ
EuroIntervention; 2012 Oct; 8(6):724-31. PubMed ID: 23086791
[TBL] [Abstract][Full Text] [Related]
15. Intravascular ultrasound analysis of small vessel lesions treated with the Sparrow coronary stent system: results of the CARE II trial.
Kume T; Waseda K; Koo BK; Yock PG; Botelho R; Verheye S; Whitbourn R; Meredith I; Worthley S; Hai KT; Honda Y; Abizaid A; Fitzgerald PJ
Catheter Cardiovasc Interv; 2014 Jan; 83(1):19-24. PubMed ID: 23413202
[TBL] [Abstract][Full Text] [Related]
16. Intravascular ultrasound insights from the Cobalt Chromium Stent With Antiproliferative for Restenosis II (COSTAR II) trial comparing CoStar and Taxus paclitaxel-eluting stents.
Tsujino I; Koizumi T; Shimohama T; Ako J; Waseda K; Krucoff M; Honda Y; Fitzgerald PJ
Cardiovasc Revasc Med; 2012; 13(2):111-8. PubMed ID: 22406056
[TBL] [Abstract][Full Text] [Related]
17. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
[TBL] [Abstract][Full Text] [Related]
18. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
[TBL] [Abstract][Full Text] [Related]
19. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.
Chevalier B; Moulichon R; Teiger E; Brunel P; Metzger JP; Pansieri M; Carrie D; Stoll HP; Wittebols K; Spaulding C; Fajadet J;
J Interv Cardiol; 2012 Dec; 25(6):586-95. PubMed ID: 22994863
[TBL] [Abstract][Full Text] [Related]
20. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions.
Grube E; Chevalier B; Guagliumi G; Smits PC; Stuteville M; Dorange C; Papeleu P; Kaul U; Džavík V
Am Heart J; 2012 May; 163(5):867-875.e1. PubMed ID: 22607866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
